Stay updated with breaking news from Dan Budwick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA acceptance of EQRx's first regulatory submission (aumolertinib)
Singular Genomics Reports Recent Highlights and Second Quarter 2022 Financial Results San Diego, CA, August 9, 2022 - Singular Genomics Systems, Inc. , a company leveraging... | August 9, 2022
-- Expert in virology, immunology and vaccine development’s appointment effective August 12 --...
09.08.2022 - Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022 John ...
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free